Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU1XOD)

• Drug Name: Nafamostat Drug Info
• Synonyms: FUT-175; Nafamostat [INN]; Nafamostatum [Latin]; UNII-Y25LQ0H97D; Nafamstat; Nafamstat Mesilate; 6-Amidino2-naphthyl 4-guanidinobenzoate; Y25LQ0H97D; CHEMBL273264; C19H17N5O2; Nafamostat (INN); p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine; Nafamostatum

Indication

Disease Entry	ICD 11	Status	REF
Pancreatitis	DC31-DC34	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[2]
Sepsis	1G40-1G41	Discontinued in Phase 2	[3]
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]

• Cross-matching ID:
  PubChem CID: 4413
  ChEBI ID: CHEBI:135466
  CAS Number: CAS 81525-10-2
  TTD Drug ID: DMU1XOD

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[8]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[9]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[10]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[11]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[12]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[13]
Etanercept	DMCV109	Arthritis	FA20	Approved	[14]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[15]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[16]
Golnerminogene pradenovac	DMKWV4B	Esophageal cancer	2B70	Phase 3	[17]

Drug(s) Targeting Serine protease unspecific (SP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabexate	DMU9D2F	Pancreatitis	DC31-DC34	Approved	[5]
Aprotinin	DM0QD4W	Bleeding disorder	GA20-GA21	Approved	[18]
Sivelestat sodium hydrate	DMOSJD0	Acute lung injury	NB32.3	Phase 4	[19]
Camostat	DMQ7UL8	Cystic fibrosis	CA25	Phase 2	[20]
VT-111a	DMY9ZGN	Acute coronary syndrome	BA41	Phase 2	[21]
Sepimostat mesylate	DMRBYH8	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[22]
VT-111	DMOY15R	Graft rejection in heart transplantation	NE84	Preclinical	[23]
NPI-1999	DMH1YL8	Thrombosis	DB61-GB90	Terminated	[24]
SDZ-MTH-958	DMKCXBJ	Artery stenosis	BD52	Terminated	[25]

Drug(s) Targeting COVID-19 spike glycoprotein (S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[26]
GSK4182136	DMYH2FI	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved in EU	[27]
LY-CoV555	DM6LVCQ	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[28]
REGN-COV2	DM0KBML	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[29]
JS016	DMGEZVF	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1/2	[30]
REGN3051	DM7LIV2	Coronavirus infection	1D92	Phase 1	[31]
REGN3048	DM0E3ZG	Coronavirus infection	1D92	Phase 1	[31]
GSK4182137	DMJJW2Y	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[27]
MERS-4	DMS6KT8	Coronavirus infection	1D92	Preclinical	[32]
MERS-27	DMVGIB4	Coronavirus infection	1D92	Preclinical	[32]

Drug(s) Targeting MERS-CoV spike glycoprotein (S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
REGN 3048	DMW08TD	Middle East Respiratory Syndrome (MERS)	1D64	Discontinue in Phase 1 Trial	[33]
REGN 3051	DMLH28J	Middle East Respiratory Syndrome (MERS)	1D64	Discontinue in Phase 1 Trial	[33]
PMID26911565-peptide-P9	DMUH012	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[34]
MERS-five-helix bundle	DMG5YRP	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[35]
Alpha-Helical lipopeptides LLS	DM3WVM4	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[36]
Peptide P21S10	DMMWQTI	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[37]
Alpha-Helical lipopeptides IIS	DM1MGBX	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[36]
Alpha-Helical lipopeptides IIK	DMVSKQF	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[36]
Alpha-Helical lipopeptides FFS	DMATQB7	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine protease unspecific (SP)	TTEMV5X	NOUNIPROTAC	Inhibitor	[5]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[6]
COVID-19 spike glycoprotein (S)	TTZ3COY	SPIKE_SARS2	Inhibitor	[7]
MERS-CoV spike glycoprotein (S)	TT85VHW	A0A140AYZ5_9BETC	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4262).
• [2] ClinicalTrials.gov (NCT04352400) Efficacy of Nafamostat in Covid-19 Patients (RACONA Study). U.S. National Institutes of Health.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006437)
• [4] Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
• [5] Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
• [6] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [7] Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
• [8] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [9] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [10] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [11] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [13] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [14] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [15] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [16] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [17] TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
• [18] Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32.
• [19] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [20] Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
• [21] Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329.
• [22] Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant. Gan To Kagaku Ryoho. 1996 Dec;23(14):1971-9.
• [23] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [24] US patent application no. 2005,0096,323, Diketopiperazine derivatives to inhibit thrombin.
• [25] Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation. 1996 Mar 27;61(6):862-8.
• [26] Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.
• [27] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [28] Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189.
• [29] REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251.
• [30] Clinical pipeline report, company report or official report of Lilly.
• [31] Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.
• [32] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [33] Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112.
• [34] A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008.
• [35] Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses. 2017 Sep 14;9(9). pii: E255.
• [36] De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745.
• [37] Discovery of Hydrocarbon-Stapled Short -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. J Med Chem. 2018 Mar 8;61(5):2018-2026.